Acquisition Deadline Looms for HilleVax Shareholders
Published on 09/14/2025 at 07:18 | Redaktion boerse-global.deThe future of clinical-stage pharmaceutical company HilleVax will be determined on Monday as the takeover bid from biotechnology specialist XOMA Royalty expires. This pivotal moment forces investors to evaluate what the proposed transaction genuinely offers.
Recent quarterly figures highlight a significant strategic shift for HilleVax. For the first half of 2025, the company reported a substantially reduced net loss of $11.3 million, a dramatic improvement from the $87.5 million loss recorded during the same period the previous year. This positive change was driven primarily by a steep reduction in research and development expenditures, which fell to $3.3 million from $52.6 million, alongside lower general and administrative costs. With a solid cash position of $159.5 million, the company enters this transaction from a position of financial strength.
Final... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
